Abstract
Obesity was first described as a low-grade inflammatory condition more than a decade ago. However, it is only relatively recently that obese individuals have been described with increased macrophage infiltration of adipose tissue, as well as an increase in the number of “M1” or “classically activated” macrophages. Furthermore, macrophages have been identified as the primary source of many of the circulating inflammatory molecules that are detected in the obese state and are postulated to be causal both in the development of insulin resistance and in the progression to type 2 diabetes. There is also novel evidence to suggest that macrophages inhibit adipocyte differentiation, potentially leading to adipocyte hypertrophy, altered secretion of adipokines and ectopic storage of lipid within liver, muscle and other non-adipose tissues. Currently, it is not clear what causes increased macrophage infiltration of adipose tissue in obese individuals. Theories include altered signalling by adipocytes, nutritional induction of metabolic endotoxemia or reduced angiogenesis and local adipose cell hypoxia. Importantly, PPAR-gamma agonists have been shown to alter macrophage phenotype to “M2” or an “alternatively activated” anti-inflammatory phenotype and may induce macrophage specific cell death. Consequently, excitement surrounds the potential for specific inhibition of macrophage infiltration of adipose tissue via pharmacotherapy for obese patients and more particularly as adjunct therapy to improve insulin sensitivity in obese individuals with insulin resistance and overt type 2 diabetes.
Keywords: Obesity, insulin resistance, inflammation, adipose tissue macrophages, type 2 diabetes
Current Pharmaceutical Design
Title: Adipose Tissue Macrophages, Low Grade Inflammation and Insulin Resistance in Human Obesity
Volume: 14 Issue: 12
Author(s): Leonie K. Heilbronn and Lesley V. Campbell
Affiliation:
Keywords: Obesity, insulin resistance, inflammation, adipose tissue macrophages, type 2 diabetes
Abstract: Obesity was first described as a low-grade inflammatory condition more than a decade ago. However, it is only relatively recently that obese individuals have been described with increased macrophage infiltration of adipose tissue, as well as an increase in the number of “M1” or “classically activated” macrophages. Furthermore, macrophages have been identified as the primary source of many of the circulating inflammatory molecules that are detected in the obese state and are postulated to be causal both in the development of insulin resistance and in the progression to type 2 diabetes. There is also novel evidence to suggest that macrophages inhibit adipocyte differentiation, potentially leading to adipocyte hypertrophy, altered secretion of adipokines and ectopic storage of lipid within liver, muscle and other non-adipose tissues. Currently, it is not clear what causes increased macrophage infiltration of adipose tissue in obese individuals. Theories include altered signalling by adipocytes, nutritional induction of metabolic endotoxemia or reduced angiogenesis and local adipose cell hypoxia. Importantly, PPAR-gamma agonists have been shown to alter macrophage phenotype to “M2” or an “alternatively activated” anti-inflammatory phenotype and may induce macrophage specific cell death. Consequently, excitement surrounds the potential for specific inhibition of macrophage infiltration of adipose tissue via pharmacotherapy for obese patients and more particularly as adjunct therapy to improve insulin sensitivity in obese individuals with insulin resistance and overt type 2 diabetes.
Export Options
About this article
Cite this article as:
Heilbronn K. Leonie and Campbell V. Lesley, Adipose Tissue Macrophages, Low Grade Inflammation and Insulin Resistance in Human Obesity, Current Pharmaceutical Design 2008; 14 (12) . https://dx.doi.org/10.2174/138161208784246153
DOI https://dx.doi.org/10.2174/138161208784246153 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Nocardia</i> Infections: Ten Years Experience from a Tertiary Health Care Center in North India (2007-2016)
Infectious Disorders - Drug Targets Nontraditional Cardiovascular Risk Factors in Pediatric Type 1 Diabetes
Current Diabetes Reviews Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Current Pharmacogenomics and Personalized Medicine The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options
Vascular Disease Prevention (Discontinued) Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis An Update on Autoinflammatory Diseases
Current Medicinal Chemistry 25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Drug Delivery Systems for Diabetes Treatment
Current Pharmaceutical Design Regulatory Mechanisms of Calcineurin Phosphatase Activity
Current Medicinal Chemistry Marine Algae as a Potential Source for Anti-diabetic Compounds - A Brief Review
Current Pharmaceutical Design Enriching One’s Environment in the Face of Cognitive and Functional Loss
Current Neurovascular Research Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics Subject Index to Volume 3
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Far-infrared Ray-mediated Antioxidant Potentials are Important for Attenuating Psychotoxic Disorders
Current Neuropharmacology An Update on Clinical and Pharmacological Aspects of Drug-Eluting Stents
Cardiovascular & Hematological Disorders-Drug Targets